StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) PT Raised to $45 at Goldman Sachs
August 28, 2018 7:48 AM
Goldman Sachs analyst Jami Rubin raised the price target on Pfizer (NYSE: PFE) to $45.00 (from $42.00) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Pfizer (PFE) Says Too Early To Comment on U.S. Pricing for Tafamidis -Bloomberg
August 27, 2018 9:23 AM
Pfizer (PFE) Reports Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results at ESC Congress 2018
August 27, 2018 5:40 AM
Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018
August 27, 2018 5:21 AM